| MCT1 | MCT4 | CD147 | GLUT1 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
n | Positive (%) | p | n | Positive (%) | p | n | Positive (%) | p | n | Positive (%) | p | |
Tumor size (cm) | ||||||||||||
 ≤4.5 | 286 | 93.4 | 0.389 | 278 | 54.7 | 0.265 | 283 | 27.9 | 0.003 | 267 | 29.6 | 0.466 |
 >4.5 | 182 | 91.2 |  | 175 | 60.0 |  | 180 | 41.1 |  | 167 | 26.3 |  |
Histological Type | ||||||||||||
 Adenocarcinoma | 417 | 92.8 | 0.456 | 402 | 57.0 | 0.862 | 411 | 33.6 | 0.787 | 386 | 28.2 | 0.389 |
 A. Mucinous | 51 | 90.2 |  | 49 | 57.1 |  | 52 | 28.8 |  | 46 | 26.1 |  |
 A. Invasive | 24 | 95.8 |  | 24 | 54.2 |  | 23 | 26.1 |  | 23 | 39.1 |  |
 Signet ring and mucinous | 4 | 75.0 |  | 3 | 33.3 |  | 4 | 25.0 |  | 4 | 0.0 |  |
Differentiation | ||||||||||||
 Well-differentiated | 219 | 93.2 | 0.271 | 213 | 56.8 | 0.070 | 217 | 34.6 | 0.875 | 202 | 21.3 | 0.009 |
 Moderately-differentiated | 209 | 93.3 |  | 204 | 55.4 |  | 206 | 32.5 |  | 197 | 35.0 |  |
 Poorly-differentiated | 49 | 85.7 |  | 43 | 69.8 |  | 48 | 29.2 |  | 43 | 39.5 |  |
 Undifferentiated | 4 | 100.0 |  | 3 | 0.0 |  | 4 | 25.0 |  | 3 | 33.3 |  |
Tumour Penetration | ||||||||||||
 Tis | 5 | 100.0 | 0.946 | 6 | 16.7 | 0.277 | 4 | 25.0 | 0.034 | 5 | 0.0 | 0.436 |
 T1 | 30 | 90.0 |  | 28 | 50.0 |  | 30 | 13.3 |  | 27 | 29.6 |  |
 T2 | 59 | 93.2 |  | 58 | 56.9 |  | 59 | 30.5 |  | 55 | 21.8 |  |
 T3 | 376 | 92.6 |  | 359 | 57.7 |  | 371 | 33.2 |  | 350 | 29.4 |  |
 T4 | 24 | 91.7 |  | 25 | 64.0 |  | 24 | 54.2 |  | 20 | 35.0 |  |
Spread to lymph nodes | ||||||||||||
 Absent | 280 | 92.5 | 0.888 | 272 | 54.0 | 0.269 | 277 | 32.5 | 0.876 | 263 | 25.5 | 0.058 |
 Present | 204 | 92.2 |  | 196 | 59.2 |  | 202 | 33.2 |  | 187 | 33.7 |  |
Vessel invasion | ||||||||||||
 Absent | 159 | 94.3 | 0.255 | 159 | 58.5 | 0.541 | 156 | 33.3 | 0.817 | 150 | 25.3 | 0.194 |
 Present | 314 | 91.4 |  | 299 | 55.5 |  | 313 | 32.3 |  | 291 | 31.3 |  |
TNM | ||||||||||||
 Stage I | 77 | 92.1 | 0.566 | 77 | 52.0 | 0.464 | 77 | 22.1 | 0.147 | 74 | 23.3 | 0.206 |
 Stage II | 183 | 92.9 |  | 179 | 57.0 |  | 181 | 36.5 |  | 173 | 26.0 |  |
 Stage III | 155 | 94.2 |  | 151 | 57.6 |  | 154 | 34.4 |  | 142 | 30.3 |  |
 Stage IV | 75 | 88.0 |  | 67 | 59.7 |  | 73 | 31.5 |  | 66 | 39.4 |  |
BRAF mutations | ||||||||||||
 Negative | 87 | 94.3 | 1.000 | 56 | 65.9 | 0.608 | 33 | 38.4 | 0.641 | 16 | 19.8 | 0.196 |
 Positive (V600E) | 4 | 100 |  | 2 | 50.0 |  | 2 | 50.0 |  | 2 | 50.0 |  |
KRAS mutations (codon12/13 and 61) | ||||||||||||
 Negative | 78 | 96.3 | 0.437 | 51 | 64.6 | 0.217 | 27 | 34.2 | 0.668 | 17 | 21.8 | 0.411 |
 Positive | 41 | 93.2 |  | 31 | 75.6 |  | 16 | 38.1 |  | 6 | 15.4 |  |
Microsatellite Instability | ||||||||||||
 Negative | 102 | 95.3 | 0.986 | 66 | 65.3 | 0.335 | 38 | 36.5 | 0.321 | 20 | 20.2 | 0.984 |
 Positive (MSI-L + MSI-H) | 20 | 95.2 |  | 16 | 76.2 |  | 5 | 25.0 |  | 4 | 20.0 |  |